Meis­sa ob­tains $30M Se­ries A from Morn­ing­side to test syn­thet­ic bi­ol­o­gy ap­proach to 'elu­sive' RSV vac­cines

Morn­ing­side Ven­tures has writ­ten a $30 mil­lion check to fu­el an ear­ly-stage ex­plo­ration of a new kind of res­pi­ra­to­ry syn­cy­tial virus.

Meis­sa Vac­cines has cho­sen …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER